Table 2

Univariable and multivariable time dependent COX regression analysis for predictors of AVEs

VariableUnivariable analysisMultivariable analysis
HR95% CIP valueHR95% CIP value
Stage 1 hypertension versus normotensives 1.771.17 to 2.680.007 1.73 1.13 to 2.65 0.0112
Stage 2 hypertension versus normotensives1.961.23 to 3.120.0047 1.65 1.01 to 2.69 0.0456
Age1.060.94 to 1.190.33112.010.96 to 4.220.064
Age squared1.0040.99 to 1.010.43960.990.99 to 1.000.0675
Female0.510.31 to 0.820.00590.700.42 to 1.740.1787
Caucasian1.160.75 to 1.800.50361.180.74 to 1.880.4771
Diabetes1.600.93 to 2.860.08911.310.73 to 2.350.3686
Dyslipidaemia*2.550.58 to 11.240.21691.710.33 to 8.830.5202
Smoking1.611.03 to 2.500.0352 1.86 1.17 to 2.96 0.0084
SLEDAI-2K1.111.07 to 1.15<0.0001 1.10 1.06 to 1.15 <0.0001
eGFR0.990.99 to 1.000.05931.000.99 to 1.000.2388
Antiphospholipid antibodies†1.701.15 to 2.530.000811.380.92 to 2.070.1236
Glucocorticoids2.021.40 to 2.920.0002 1.76 1.19 to 2.60 0.0043
Anticoagulants/antiplatelets3.052.09 to 4.46<0.0001 3.34 2.25 to 4.94 <0.0001
  • Bold indicates variables associated with increased risk for atherosclerotic vascular events in the multivariable analysis.

  • *Abnormal total cholesterol or low-density lipoprotein for two consecutive visits.

  • †Lupus anticoagulant and/or anticardiolipin antibodies (IgM, IgG).

  • AVE, atherosclerotic vascular event; eGFR, estimated glomerular filtration rate; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.